Blog - Page 12 of 16

SOFIE Submits Investigational New Drug Application to US FDA for Pancreatic Cancer Imaging
Gallery
SOFIE Submits Investigational New Drug Application to US FDA for Pancreatic Cancer Imaging

SOFIE Submits Investigational New Drug Application to US FDA for Pancreatic Cancer Imaging

Dulles, VA – October 12, 2021 – SOFIE Biosciences (SOFIE), an established US manufacturer and […]

sofie_c557hm2025-10-15T16:40:47+00:0012, Oct 2021|News|

New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
Gallery
New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress

New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress

Surachet Imlimthan, Euy Sung Moon, Hendrik Rathke, Ali Afshar-Oromieh, Frank Rösch, Axel […]

sofie_c557hm2022-06-30T15:08:38+00:005, Oct 2021|Publications|

SOFIE promotes Scott Boller to Chief Financial Officer
Gallery
SOFIE promotes Scott Boller to Chief Financial Officer

SOFIE promotes Scott Boller to Chief Financial Officer

SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, has promoted the company’s […]

sofie_c557hm2025-10-15T16:41:07+00:0024, Sep 2021|News|

Dr. Michael E. Phelps Awarded the Pioneer in Medicine Award from the Society of Brain Mapping & Therapeutics
Gallery
Dr. Michael E. Phelps Awarded the Pioneer in Medicine Award from the Society of Brain Mapping & Therapeutics

Dr. Michael E. Phelps Awarded the Pioneer in Medicine Award from the Society of Brain Mapping & Therapeutics

The Society for Brain Mapping and Therapeutics (SBMT), the leading multi-specialty association for Brain Mapping, is […]

sofie_c557hm2025-10-13T13:33:55+00:009, Jul 2021|News|

SOFIE to Commercially Supply FDA-Approved PYLARIFY® (piflufolastat F 18) Injection
Gallery
SOFIE to Commercially Supply FDA-Approved PYLARIFY® (piflufolastat F 18) Injection

SOFIE to Commercially Supply FDA-Approved PYLARIFY® (piflufolastat F 18) Injection

SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, will be commercially […]

sofie_c557hm2025-10-15T16:41:29+00:0028, May 2021|News|

Brian Schumer joins SOFIE as Chief Operating Officer
Gallery
Brian Schumer joins SOFIE as Chief Operating Officer

Brian Schumer joins SOFIE as Chief Operating Officer

We are excited to welcome Brian Schumer to the SOFIE team. Brian joins SOFIE […]

jsctek_u4g7i52025-10-13T13:34:07+00:006, May 2021|News|

SOFIE executes order to purchase a top-of-the line GE PETtrace 890
Gallery
SOFIE executes order to purchase a top-of-the line GE PETtrace 890

SOFIE executes order to purchase a top-of-the line GE PETtrace 890

SOFIE has placed a purchase order for GE […]

jsctek_u4g7i52025-10-15T16:41:29+00:0015, Apr 2021|News|

SOFIE affiliate, iTheranostics, executes agreement for its promising library of Fibroblast Activation Protein (FAP) targeted theranostics
Gallery
SOFIE affiliate, iTheranostics, executes agreement for its promising library of Fibroblast Activation Protein (FAP) targeted theranostics

SOFIE affiliate, iTheranostics, executes agreement for its promising library of Fibroblast Activation Protein (FAP) targeted theranostics

Novartis has acquired global development and commercial rights to therapeutic applications for iTheranostics’ library […]

jsctek_u4g7i52025-10-15T16:39:34+00:0030, Mar 2021|News|

SOFIE Inc. enters into partnership with AUGMENTICON™
Gallery
SOFIE Inc. enters into partnership with AUGMENTICON™

SOFIE Inc. enters into partnership with AUGMENTICON™

AUGMENTICON™, a privately held technology company developing Augmented-/Mixed-Reality (AR-/MR)-tools for a cost-effective, high-quality manufacturing […]

jsctek_u4g7i52025-10-13T13:34:19+00:0016, Mar 2021|News|

FAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
Gallery
FAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients

FAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients

Frederik L Giesel¹, Sebastian Adeberg

jsctek_u4g7i52025-10-15T16:39:34+00:0024, Feb 2021|Publications|

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.